<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01978444</url>
  </required_header>
  <id_info>
    <org_study_id>TJ-20131101</org_study_id>
    <nct_id>NCT01978444</nct_id>
  </id_info>
  <brief_title>Study on Laparoscopic D2 Lymphadenectomy Plus Complete Mesogastrium Excision（D2+CME）for Advanced Gastric Cancer</brief_title>
  <official_title>Prospective Randomized Controlled Trial of Laparoscopic D2 Lymphadenectomy Plus Complete Mesogastrium Excision（D2+CME）vs. Laparoscopic D2 Lymphadenectomy for Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radical gastrectomy for gastric cancer with D2 lymph node dissection has been widely applied
      in advanced gastric cancer. However,for most patients,tumor local-regional recurrence has
      been proven unavoidable.

      Recently, many clinical studies have proved that some cancer cells and cancer nodes exist in
      the mesogastrium which can be hardly removed by conventional radical gastrectomy with D2
      lymphadenectomy. It is suggested that Complete mesogastrium excision (CME) is imperative and
      should be added to D2 lymphadenectomy in order to reduce the risk of local recurrence.

      Thus, the comparison of short-term and long-term outcome between laparoscopic D2
      lymphadenectomy plus complete mesogastrium excision and conventional laparoscopic D2
      lymphadenectomy for locally advanced gastric cancer based on a well designed randomized
      controlled trial is needed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      N.A.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease free survival</measure>
    <time_frame>36 months</time_frame>
    <description>3-years disease-free survival of the enrolled patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative recovery course</measure>
    <time_frame>10 days</time_frame>
    <description>Time to first ambulation, flatus, liquid diet, soft diet, and duration of hospital stay. The amount of abdominal drainage and blood transfusion are also recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity and mortality</measure>
    <time_frame>30 days; 36 months</time_frame>
    <description>The early postoperative complication and mortality are defined as the event observed within 30 days after surgery, while the time frame for late complication is the period from postoperative day 31th to the end of month 36th.
3-year overall survival rate [ Time Frame: 36 months ] [ Designated as safety issue: No ]
3-year recurrence pattern [ Time Frame: 36 months ] [ Designated as safety issue: No ]
Recurrence patterns are classified into five categories at the time of first diagnosis: locoregional, hematogenous, peritoneal, distant lymph node, and mixed type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>3-years overall survival of the enrolled patients</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Postoperative intraperitoneal free cancer cell (IFCC)</measure>
    <time_frame>within 1hour</time_frame>
    <description>Positive rate of cancer cells from intraperitoneal wash samples after gastrectomy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">167</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>laparoscopic D2 lymphadenectomy plus CME</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic D2 lymphadenectomy plus CME will be performed for the treatment of patients assigned to this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>laparoscopic D2 lymphadenectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laparoscopic D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic D2 lymphadenectomy plus CME</intervention_name>
    <arm_group_label>laparoscopic D2 lymphadenectomy plus CME</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic D2 lymphadenectomy</intervention_name>
    <arm_group_label>laparoscopic D2 lymphadenectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age from over 18 to under 75 years Primary gastric adenocarcinoma (papillary, tubular,
        mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by
        endoscopic biopsy cT2-4a, N0-3, M0 at preoperative evaluation according to the AJCC Cancer
        Staging Manual Seventh Edition Expected curative resection through gastrectomy with D2
        lymphadenectomy Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group)
        scale ASA (American Society of Anesthesiology) score class I, II, or III Informed consent
        obtained from patients or their appointed agent

        Exclusion Criteria:

        Patients treated with neoadjuvant chemotherapy or radiation therapy; Patients with history
        of upper abdominal surgery; History with other severe comorbidities and cannot tolerate
        laparoscopic surgery, such as severe heart and lung diseases, heart function below clinical
        stage 2, pulmonary infection, moderate to severe COPD, chronic bronchitis, severe diabetes
        and / or renal insufficiency, severe hepatitis and / or function below the rank of CHILD B
        grade, and severe malnutrition, etc; Patients suffering from malignant diseases before the
        study or with other gastric malignant diseases, such as lymphoma and stromal tumors, etc.;
        Pregnant woman and woman during lactation; Patients with mental sickness; The patient
        compliance is bad or the researcher expect there will not be good patient compliance;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianping Gong, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianping Gong, M.D.,Ph.D.</last_name>
    <phone>+86 13607189315</phone>
    <email>jpgong@tjh.tjmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daxing Xie, M.D.,Ph.D.</last_name>
    <phone>+86 18971560785</phone>
    <email>xdx618@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College in Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianping Gong, M.D.,Ph.D.</last_name>
      <phone>+86 13607189315</phone>
      <email>jpgong@tjh.tjmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Daxing Xie, M.D.,Ph.D.</last_name>
      <phone>+86 18971560785</phone>
      <email>dxxie@tjh.tjmu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Sasako M, Saka M, Fukagawa T, Katai H, Sano T. Surgical treatment of advanced gastric cancer: Japanese perspective. Dig Surg. 2007;24(2):101-7. Epub 2007 Apr 19. Review.</citation>
    <PMID>17446702</PMID>
  </reference>
  <reference>
    <citation>Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, Lui WY, Whang-Peng J. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006 Apr;7(4):309-15.</citation>
    <PMID>16574546</PMID>
  </reference>
  <reference>
    <citation>Menges M, Hoehler T. Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction. J Cancer Res Clin Oncol. 2009 Jan;135(1):29-38. doi: 10.1007/s00432-008-0425-z. Epub 2008 Jun 4. Review.</citation>
    <PMID>18523800</PMID>
  </reference>
  <reference>
    <citation>Nakamura K, Ozaki N, Yamada T, Hata T, Sugimoto S, Hikino H, Kanazawa A, Tokuka A, Nagaoka S. Evaluation of prognostic significance in extracapsular spread of lymph node metastasis in patients with gastric cancer. Surgery. 2005 May;137(5):511-7.</citation>
    <PMID>15855922</PMID>
  </reference>
  <reference>
    <citation>Nagatomo A, Abe N, Takeuchi H, Yanagida O, Masaki T, Mori T, Sugiyama M, Ohkura Y, Fujioka Y, Atomi Y. Microscopic cancer cell spread in gastric cancer: whole-section analysis of mesogastrium. Langenbecks Arch Surg. 2009 Jul;394(4):655-60. doi: 10.1007/s00423-008-0427-y. Epub 2008 Oct 18.</citation>
    <PMID>18931855</PMID>
  </reference>
  <results_reference>
    <citation>Xie D, Osaiweran H, Liu L, Wang X, Yu C, Tong Y, Hu J, Gong J. Mesogastrium: a fifth route of metastasis in gastric cancer? Med Hypotheses. 2013 Apr;80(4):498-500. doi: 10.1016/j.mehy.2012.12.020. Epub 2013 Feb 10.</citation>
    <PMID>23403142</PMID>
  </results_reference>
  <results_reference>
    <citation>Xie D, Yu C, Liu L, Osaiweran H, Gao C, Hu J, Gong J. Short-term outcomes of laparoscopic D2 lymphadenectomy with complete mesogastrium excision for advanced gastric cancer. Surg Endosc. 2016 Nov;30(11):5138-5139. Epub 2016 Mar 22.</citation>
    <PMID>27005289</PMID>
  </results_reference>
  <results_reference>
    <citation>Xie D, Gao C, Lu A, Liu L, Yu C, Hu J, Gong J. Proximal segmentation of the dorsal mesogastrium reveals new anatomical implications for laparoscopic surgery. Sci Rep. 2015 Nov 6;5:16287. doi: 10.1038/srep16287.</citation>
    <PMID>26542081</PMID>
  </results_reference>
  <results_reference>
    <citation>Xie D, Liu L, Osaiweran H, Yu C, Sheng F, Gao C, Hu J, Gong J. Detection and Characterization of Metastatic Cancer Cells in the Mesogastrium of Gastric Cancer Patients. PLoS One. 2015 Nov 13;10(11):e0142970. doi: 10.1371/journal.pone.0142970. eCollection 2015. Erratum in: PLoS One. 2016;11(1):e0148681.</citation>
    <PMID>26566136</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2013</study_first_submitted>
  <study_first_submitted_qc>October 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2013</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Jianping Gong</investigator_full_name>
    <investigator_title>Director of Department of General Surgery</investigator_title>
  </responsible_party>
  <keyword>D2 lymphadenectomy</keyword>
  <keyword>Complete Mesogastrium Excision</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

